Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 316

The DOI matches its Crossref record.

PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer

Dulos, John, Carven, Gregory J., van Boxtel, Susan J., Evers, Sabine, Driessen-Engels, Lilian J. A., Hobo, Willemijn, Gorecka, Monika A., de Haan, Anton F. J., Mulders, Peter, Punt, Cornelis J. A., Jacobs, Joannes F. M., Schalken, Jack A., Oosterwijk, Egbert, van Eenennaam, Hans, Boots, Annemieke M.·2012·Journal of Immunotherapy

Abstract

Negative costimulation on T cells is exploited by both prostate cancer and melanoma to evade antitumor immunity. Blocking such mechanisms restores antitumor immunity as was demonstrated by the improved survival of patients with metastatic melanoma after treatment with an antibody blocking the CTLA-4 inhibitory receptor (ipilimumab). Enhanced expression of another inhibitory immunoreceptor, programmed death-1 (PD-1), and its ligand, PD-L1, was found to correlate with a poor prognosis in prostate cancer and melanoma. PD-1-blocking antibodies are being developed to modulate antitumor immune responses. To support preclinical and clinical development of anti-PD-1 therapy, we sought to develop biomarker assays that can detect the effect of PD-1-blocking agents in whole blood and peripheral blood mononuclear cells. In this study, we assessed the effect of PD-1 blockade in modulating super antigen (staphylococcus enterotoxin B)-induced and recall antigen (tetanus toxoid)-induced T-cell reactivity in vitro using whole blood and peripheral blood mononuclear cells from patients with advanced melanoma, prostate cancer, and healthy controls. PD-1 blockade was found to shift antigen-induced cellular reactivity toward a proinflammatory Th1/Th17 response, as evidenced by enhanced production of interferon γ, interleukin (IL)-2, tumor necrosis factor α, IL-6, and IL-17 and reduced production of the Th2 cytokines IL-5 and IL-13. It is interesting to note that suppression of Th2 responsivity was seen with whole blood cells only from patients with cancer. Taken together, we identified novel biomarker assays that might be used to determine the functional consequences of PD-1 blockade in peripheral blood cells from patients with cancer. How these assays translate to the local antitumor response remains to be established in a clinical setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/cji.0b013e318247a4e7

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 316

Metadata

Authors
Dulos, J., Carven, G. J., van Boxtel, S. J., Evers, S., Driessen-Engels, L. J. A., Hobo, W., Gorecka, M. A., de Haan, A. F. J., Mulders, P., Punt, C. J. A., Jacobs, J. F. M., Schalken, J. A., Oosterwijk, E., van Eenennaam, H., & Boots, A. M.
Venue
Journal of Immunotherapy
Published
2012-02
Volume
35
Issue
2
Pages
169-178
ISSN
1524-9557 (ISSN-L)
OpenAlex
W2098205979
Cited by
316
References
0
FWCI
4.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer. https://app.cochat.ai/papers/10.1097/cji.0b013e318247a4e7
The paper
Dulos, J., Carven, G. J., van Boxtel, S. J., Evers, S., Driessen-Engels, L. J. A., Hobo, W., Gorecka, M. A., de Haan, A. F. J., Mulders, P., Punt, C. J. A., Jacobs, J. F. M., Schalken, J. A., Oosterwijk, E., van Eenennaam, H., & Boots, A. M. (2012). PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer. Journal of Immunotherapy. https://doi.org/10.1097/cji.0b013e318247a4e7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.